Motus GI Announces Pricing of Initial Public Offering

FORT LAUDERDALE, FL--(Marketwired - February 14, 2018) - Motus GI Holdings, Inc., ("Motus" or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today the pricing of its initial public offering of 3,500,000 shares of its common stock at a public offering price of $5.00 per share. All of the shares of common stock are being offered by Motus. The shares are expected to begin trading on the NASDAQ Capital Market on February 14, 2018 under the ticker symbol "MOTS." In addition Motus has granted the underwriters a 30-day option to purchase an additional 525,000 shares of its common stock at the initial public offering price, less the underwriting discount and commissions, to cover over-allotments. The closing of the offering is expected to occur on February 16, 2018, subject to the satisfaction of customary closing conditions.

Piper Jaffray & Co. is acting as the sole book-running manager and Oppenheimer & Co. is acting as lead manager for the offering.

A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to this offering when available, may be obtained from Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN, 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Motus
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.

Forward-Looking Statements
This press release contains certain forward-looking statements, including those relating to the regarding the anticipated timing of completion of the offering and other statements that are predictive in nature. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission, including its registration statement on Form S-1, as amended from time to time, under the caption "Risk Factors."